Future Products

Products to be developed in Phase III Commercialization:  AGT's first product, a blood-based diagnostic, successfully developed by our NIH-funded Fast Track Phase I/II project, will be fur­ther advanced to Phase III commercialization of our project in three areas: 

  • Second population validation of results from the Canadian patient population;
  • Comparing AD miR indices with MRI imaging tests, as a combinatory diagnostic approach;

Seeking partnership with large pharma to further the database of AD blood tests for commercialization, FDA approval, product launching, and market entry.